Assaf Friedler

A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants.

Inhibition of nuclear import by backbone cyclic peptidomimetics derived from the HIV-1 MA NLS sequence.

HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases.

Two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53.

Human immunodeficiency virus type 1 Vif binds the viral protease by interaction with its N-terminal region.

The structure of an FF domain from human HYPA/FBP11.

Molecular mechanism of the interaction between MDM2 and p53.

Kinetic instability of p53 core domain mutants: implications for rescue by small molecules.

Cooperative organization in a macromolecular complex.

Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide.

Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for "mutant conformation".

Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes.

Comparison of BRCT domains of BRCA1 and 53BP1: a biophysical analysis.

Binding of Rad51 and other peptide sequences to a promiscuous, highly electrostatic binding site in p53.

Modulation of binding of DNA to the C-terminal domain of p53 by acetylation.

Butyrylcholinesterase attenuates amyloid fibril formation in vitro.

Interaction between HIV-1 Rev and integrase proteins: a basis for the development of anti-HIV peptides.

Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium.

Expression and characterization of a novel reverse transcriptase of the LTR retrotransposon Tf1.

The DNA damage response mediator MDC1 directly interacts with the anaphase-promoting complex/cyclosome.

Using peptides to study the interaction between the p53 tetramerization domain and HIV-1 Tat.

Correlation between shiftide activity and HIV-1 integrase inhibition by a peptide selected from a combinatorial library.

Peptides derived from HIV-1 Rev inhibit HIV-1 integrase in a shiftide mechanism.

Synthesis of a novel macrocyclic library: discovery of an IGF-1R inhibitor.

The structure and interactions of the proline-rich domain of ASPP2.

Molecular basis of the interaction between the antiapoptotic Bcl-2 family proteins and the proapoptotic protein ASPP2.

Design and synthesis of backbone cyclic phosphorylated peptides: The IkappaB model.

Peptides derived from HIV-1 integrase that bind Rev stimulate viral genome integration.

The C-terminal domain of the HIV-1 Vif protein is natively unfolded in its unbound state.

A model for the interaction between NF-kappa-B and ASPP2 suggests an I-kappa-B-like binding mechanism.

Peptide inhibitors of HIV-1 integrase: from mechanistic studies to improved lead compounds.

Integration of HIV-1 DNA is regulated by interplay between viral rev and cellular LEDGF/p75 proteins.

Novel regulation of HIV-1 replication and pathogenicity: Rev inhibition of integration.

The positively charged region of the myosin IIC non-helical tailpiece promotes filament assembly.

A novel role for the viral Rev protein in promoting resistance to superinfection by human immunodeficiency virus type 1.

Over-expression of the HIV-1 Rev promotes death of nondividing eukaryotic cells.

Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.

Structural disorder in the HIV-1 Vif protein and interaction-dependent gain of structure.

Peptide-modified "smart" hydrogels and genetically engineered stem cells for skeletal tissue engineering.

Stimulation of the HIV-1 integrase enzymatic activity and cDNA integration by a peptide derived from the integrase protein.

The ASPP interaction network: electrostatic differentiation between pro- and anti-apoptotic proteins.

Oxidation of Helix-3 methionines precedes the formation of PK resistant PrP.

The C terminus of p53 binds the N-terminal domain of MDM2.

Peptides derived from the HIV-1 integrase promote HIV-1 infection and multi-integration of viral cDNA in LEDGF/p75-knockdown cells.

Specific eradication of HIV-1 from infected cultured cells.

A family of cell-adhering peptides homologous to fibrinogen C-termini.

Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein.

From peptides to proteins: lessons from my years at the Centre for Protein Engineering.

Critical scaffolding regions of the tumor suppressor Axin1 are natively unfolded.

Peptides that bind the HIV-1 integrase and modulate its enzymatic activity--kinetic studies and mode of action.

Studying protein-protein interactions using peptide arrays.

Crowding alone cannot account for cosolute effect on amyloid aggregation.

Transportin 3 and importin α are required for effective nuclear import of HIV-1 integrase in virus-infected cells.

Nucleocytoplasmic shuttling of HIV-1 integrase is controlled by the viral Rev protein.

The effect of tachykinin neuropeptides on amyloid β aggregation.

Using peptides to study protein-protein interactions.

Chemical synthesis and expression of the HIV-1 Rev protein.

Mechanism of the interaction between the intrinsically disordered C-terminus of the pro-apoptotic ARTS protein and the Bir3 domain of XIAP.

Exposure of bipartite hydrophobic signal triggers nuclear quality control of Ndc10 at the endoplasmic reticulum/nuclear envelope.

A structural model of the HIV-1 Rev-integrase complex: the molecular basis of integrase regulation by Rev.

Peptides mimicking the unique ARTS-XIAP binding site promote apoptotic cell death in cultured cancer cells.

Molecular basis of the interaction between proapoptotic truncated BID (tBID) protein and mitochondrial carrier homologue 2 (MTCH2) protein: key players in mitochondrial death pathway.

A comparative study of backbone versus side chain peptide cyclization: application for HIV-1 integrase inhibitors.

Specific recognition of p53 tetramers by peptides derived from p53 interacting proteins.

Peptides that inhibit HIV-1 integrase by blocking its protein-protein interactions.

Revealing the ligand binding site of NhaA Na+/H+ antiporter and its pH dependence.

High resolution characterization of myosin IIC protein tailpiece and its effect on filament assembly.

Monitoring the HIV-1 integrase enzymatic activity using atomic force microscopy in a 2LTR system.

Regulation of ASPP2 interaction with p53 core domain by an intramolecular autoinhibitory mechanism.

Mapping the Vif-A3G interaction using peptide arrays: a basis for anti-HIV lead peptides.

The STIL protein contains intrinsically disordered regions that mediate its protein-protein interactions.

Characterization of the translocation-competent complex between the Helicobacter pylori oncogenic protein CagA and the accessory protein CagF.

acetylation of lysine 382 and phosphorylation of serine 392 in p53 modulate the interaction between p53 and MDC1 in vitro.

A highly efficient in situ N-acetylation approach for solid phase synthesis.

Cation diffusion facilitators transport initiation and regulation is mediated by cation induced conformational changes of the cytoplasmic domain.

Integrated strategy reveals the protein interface between cancer targets Bcl-2 and NAF-1.

Allosteric modulation of protein oligomerization: an emerging approach to drug design.

Bacterial magnetosome biomineralization--a novel platform to study molecular mechanisms of human CDF-related Type-II diabetes.

A tandem in situ peptide cyclization through trifluoroacetic acid cleavage.

A role of disordered domains in regulating protein oligomerization and stability.

The disordered region of Arabidopsis VIP1 binds the Agrobacterium VirE2 protein outside its DNA-binding site.